FIELD: medicine, pharmaceutics.
SUBSTANCE: claimed invention relates to pharmaceutical composition, which contains compound of insulin in concentration, sufficient for supplying therapeutically effective level of insulin compound in blood plasma for at least 3 days. Insulin compound relates to pro-medical compound, which represents insulin conjugate with linker, bound with hydrogel carrier. Also described is suspension, containing pharmaceutical composition of insulin conjugate, method of suspension obtaining, set, including pharmaceutical composition of insulin conjugate and container for introduction of composition.
EFFECT: pharmaceutical composition of insulin conjugate by invention is characterised by the fact that it has pharmacokinetic profile in vivo in fact without release of insulin compound.
26 cl, 9 dwg, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PRODRUGS CONTAINING INSULIN LINKER CONJUGATE | 2010 |
|
RU2574667C2 |
| PRODRUGS CONTAINING EXENDIN CONJUGATE-LINKER | 2011 |
|
RU2593774C2 |
| DIAGNOSIS, PREVENTION AND TREATMENT OF JOINT DISEASES | 2013 |
|
RU2682676C2 |
| HYDROCARBON GEL-BASED PRODRUGS | 2013 |
|
RU2647729C2 |
| VEGF NEUTRALISING PRODRUGS FOR THE TREATMENT OF OCULAR CONDITIONS | 2013 |
|
RU2673881C2 |
| BIODEGRADABLE WATER-INSOLUBLE POLYETHYLENEGLYCOL-BASED HYDROGELS | 2010 |
|
RU2554854C9 |
| PRODRUG CONTAINING SELF-CLEAVABLE LINKER | 2014 |
|
RU2676324C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| PRODRUG CONTAINING A SELF-CLEAVABLE LINKER | 2018 |
|
RU2798085C2 |
| PHARMACEUTICAL COMPOSITION AND METHOD OF TREATING GROWTH HORMONE-ASSOCIATED DISEASES IN HUMANS | 2014 |
|
RU2689336C2 |
